CO6311007A2 - Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+, efectiva a dosis bajas - Google Patents

Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+, efectiva a dosis bajas

Info

Publication number
CO6311007A2
CO6311007A2 CO10127114A CO10127114A CO6311007A2 CO 6311007 A2 CO6311007 A2 CO 6311007A2 CO 10127114 A CO10127114 A CO 10127114A CO 10127114 A CO10127114 A CO 10127114A CO 6311007 A2 CO6311007 A2 CO 6311007A2
Authority
CO
Colombia
Prior art keywords
agent
cells
pharmaceutical composition
effective
low dose
Prior art date
Application number
CO10127114A
Other languages
English (en)
Inventor
Frank Osterroth
Silke Aigner
Christoph Uherek
Matthias Germer
Elmar Kraus
Andrea Wartenberg-Demand
Daniele Wolf
Sibylle Kaiser
Juergen Lindner
Christoph Bruecher
Benjamin Daelken
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0804686A external-priority patent/GB0804686D0/en
Priority claimed from GB0817811A external-priority patent/GB0817811D0/en
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of CO6311007A2 publication Critical patent/CO6311007A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona una composición farmacéutica para tratar una enfermedad autoimmune, que comprende un portador farmacéutico aceptable y un agente capaz de activar células T regulatorias CD4+C025+, en donde la composición se va a administrar a un sujeto en una dosis del agente de 0.2 mg a 30 mg.
CO10127114A 2008-03-13 2010-10-13 Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+, efectiva a dosis bajas CO6311007A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0804686A GB0804686D0 (en) 2008-03-13 2008-03-13 Humanized antibody
GB0817811A GB0817811D0 (en) 2008-09-29 2008-09-29 Agent for treating disease

Publications (1)

Publication Number Publication Date
CO6311007A2 true CO6311007A2 (es) 2011-08-22

Family

ID=40756949

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10127114A CO6311007A2 (es) 2008-03-13 2010-10-13 Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+, efectiva a dosis bajas

Country Status (16)

Country Link
US (1) US9334325B2 (es)
EP (1) EP2265643B1 (es)
JP (1) JP5597553B2 (es)
KR (1) KR20100135257A (es)
CN (1) CN102027017A (es)
AU (1) AU2009231325B2 (es)
BR (1) BRPI0909048A2 (es)
CA (1) CA2718184A1 (es)
CO (1) CO6311007A2 (es)
CR (1) CR11724A (es)
IL (1) IL207891A0 (es)
MX (1) MX2010010028A (es)
RU (1) RU2539110C2 (es)
SG (1) SG190598A1 (es)
WO (1) WO2009121690A1 (es)
ZA (1) ZA201007215B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7832566B2 (en) 2002-05-24 2010-11-16 Biomet Biologics, Llc Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles
US20060278588A1 (en) 2002-05-24 2006-12-14 Woodell-May Jennifer E Apparatus and method for separating and concentrating fluids containing multiple components
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
US8034014B2 (en) 2007-03-06 2011-10-11 Biomet Biologics, Llc Angiogenesis initation and growth
US20080269762A1 (en) * 2007-04-25 2008-10-30 Biomet Manufacturing Corp. Method and device for repair of cartilage defects
EP2259774B1 (en) 2008-02-27 2012-12-12 Biomet Biologics, LLC Methods and compositions for delivering interleukin-1 receptor antagonist
US8753690B2 (en) * 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
CA2718191C (en) * 2008-03-13 2018-05-15 Biotest Ag Agent for treating disease
BRPI0909179A2 (pt) * 2008-03-13 2015-08-25 Biotest Ag Composição farmacêutica, e, método de tratamento de uma doença autoimune.
CA2738598C (en) * 2008-09-29 2017-11-21 Biotest Ag Composition for treating disease
US20110052561A1 (en) * 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
EP2470162B1 (en) 2009-08-27 2019-03-27 Biomet Biologics, LLC Implantable device for production of interleukin-1 receptor antagonist
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP2977054A1 (en) 2010-09-03 2016-01-27 Biomet Biologics, LLC Methods and compositions for delivering interleukin-1 receptor antagonist
US9011846B2 (en) 2011-05-02 2015-04-21 Biomet Biologics, Llc Thrombin isolated from blood and blood fractions
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
EP3074507B1 (en) 2013-11-26 2022-01-05 Biomet Biologics, LLC Methods of mediating macrophage phenotypes
WO2015125652A1 (ja) * 2014-02-21 2015-08-27 Ｉｄａｃセラノスティクス株式会社 固形がんの治療剤
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT90657B (pt) 1988-05-27 1995-03-01 Ortho Pharma Corp Processo para a preparacao de peptidos que bloqueiam a ligacao de hiv-1 a proteina cd4 receptora
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0462229A4 (en) 1989-05-02 1992-03-11 Genelabs Incorporated Chemically modified cd4 peptide fragments having anti-retroviral properties
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
GB8912497D0 (en) 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US20020099179A1 (en) * 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
HUT60768A (en) 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
US7084260B1 (en) * 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
JPH05505112A (ja) * 1990-11-27 1993-08-05 バイオジェン，インコーポレイテッド Ａｉｄｓ、ａｒｃおよびｈｉｖ感染の予防および治療に有用な抗ｃｄ４抗体ホモログ
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5777085A (en) * 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
IL101769A (en) 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
US5741488A (en) 1992-10-08 1998-04-21 The Kennedy Institute For Rheumatology Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies
WO1995009652A1 (en) 1993-10-06 1995-04-13 The Kennedy Institute For Rheumatology Treatment of autoimmune and inflammatory disorders
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
EP0614984B2 (en) * 1993-03-05 2010-11-03 Bayer HealthCare LLC Anti-TNF alpha human monoclonal antibodies
EP0631783A1 (en) 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
US20020068057A1 (en) * 1994-03-10 2002-06-06 Marc Feldmann Treatment of autoimmune and inflammatory disorders
CA2221350A1 (en) 1995-05-18 1996-11-21 Ortho Pharmaceutical Corporation Induction of immunological tolerance by the use of non-depleting anti-cd4 antibodies
CN103275221B (zh) 1996-02-09 2016-08-17 艾伯维生物技术有限公司 结合人TNFα的人抗体
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
WO1998014211A1 (en) 1996-10-01 1998-04-09 Celltech Therapeutics Limited Pharmaceutical products containing protein-tyrosine kinase inhibitors and anti-cd4 antibodies
DE19722888A1 (de) * 1997-05-28 1998-12-03 Thomas Prof Dr Huenig Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten
AU3633000A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
EP1194167B1 (en) * 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
EP1289554A4 (en) 2000-06-02 2004-05-26 Univ Minnesota IMMUNOTHERAPEUTIC PROCESS FOR PREVENTING REJECTION OF ISLAND CELLS
WO2002022212A2 (en) * 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
DE10050935A1 (de) * 2000-10-11 2002-05-02 Tegenero Gmbh Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
RU2345719C2 (ru) 2001-01-16 2009-02-10 Васкулар Терапиез, Ллс. Способ предотвращения или лечения уменьшения доступа для гемодиализа сосудов и устройство для его осуществления и другие сосудистые графты
CA2440649A1 (en) * 2001-03-07 2002-09-19 Children's Medical Center Corporation Method to screen peptide display libraries using minicell display
EP1241249A1 (en) 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
GB2376466A (en) 2001-06-14 2002-12-18 Mark Frewin TRX1 antibody
DE60238533D1 (de) 2001-06-14 2011-01-20 Cambridge Entpr Ltd Nicht-depletierender Antikörper TRX-1 gegen CD4 und dessen Verwendungen
US7541443B2 (en) * 2001-06-14 2009-06-02 Tolerrx, Inc. Anti-CD4 antibodies
WO2003048194A2 (de) * 2001-12-04 2003-06-12 Tegenero Ag Peptid oder protein enthaltend ein c'-d loop der cd28 rezeptorfamilie
DE10212108A1 (de) * 2002-03-13 2003-10-02 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
DE10230223A1 (de) * 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
EP1578364A4 (en) 2002-09-16 2011-06-08 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISEASES
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7501494B2 (en) * 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
WO2004091657A2 (en) * 2003-04-09 2004-10-28 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
GB0314461D0 (en) 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
EP1658308A1 (en) 2003-08-25 2006-05-24 Pieris ProteoLab AG Muteins of a bilin-binding protein with affinity for a given target
EP1600164A3 (de) * 2003-09-22 2006-05-17 TeGenero AG Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
DE10352900A1 (de) * 2003-11-11 2005-06-16 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
EP1758936A2 (en) 2004-06-22 2007-03-07 Tolerrx Inc. Optimized dosing with anti-cd4 antibodies for tolerance induction in primates
CN101031305A (zh) * 2004-09-29 2007-09-05 兴和株式会社 类风湿性关节炎的预防和/或治疗药物
EP2171060B1 (de) 2004-11-11 2013-10-02 TheraMAB LLC Superagonistische anti-cd28 antikörper
WO2006055077A2 (en) 2004-11-12 2006-05-26 The University Of North Carolina At Charlotte Modulation of cd4+ t cell responses by a tick saliva protein, salp15 and polypeptides derived therefrom
DE102004063494A1 (de) * 2004-12-23 2006-07-13 Tegenero Ag Antikörper
JP4730733B2 (ja) * 2005-05-02 2011-07-20 国立大学法人京都大学 ４型葉酸受容体の発現を指標とした制御性ｔ細胞の検出方法、及び免疫賦活剤
SG163615A1 (en) * 2005-07-11 2010-08-30 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
CN101287493A (zh) 2005-08-18 2008-10-15 根马布股份公司 采用cd4结合肽和辐射的疗法
SG192479A1 (en) * 2005-08-26 2013-08-30 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
TWI596111B (zh) 2006-01-05 2017-08-21 建南德克公司 抗ｅｐｈｂ４抗體及使用該抗體之方法
EP2001510A4 (en) * 2006-03-16 2010-06-09 Genentech Inc METHODS OF TREATING LUPUS USING CD4 ANTIBODIES
JP2009529915A (ja) 2006-03-20 2009-08-27 ゾーマ テクノロジー リミテッド ガストリン物質に対して特異的なヒト抗体および方法
US20090208471A1 (en) 2006-04-07 2009-08-20 Yun Theodore J Isolation and Use of Human Regulatory T Cells
WO2007135684A2 (en) 2006-05-22 2007-11-29 Hadasit Medical Research Services & Development Limited Method of treatment of anti-cd4 autoimmunity
JP5867795B2 (ja) 2007-02-01 2016-02-24 テーツェーエフ ゲゼルシャフト ミット ベシュレンクテル ハフツング 調節性ｔ細胞の特異的活性化ならびに喘息、アレルギー疾患、自己免疫疾患、移植片拒絶の治療および免疫寛容の誘導のためのその使用
EP2599791A1 (en) 2007-04-27 2013-06-05 Genentech, Inc. Potent, stable and non-immunosuppressive anti-CD4 antibodies
BRPI0909179A2 (pt) * 2008-03-13 2015-08-25 Biotest Ag Composição farmacêutica, e, método de tratamento de uma doença autoimune.
CA2718191C (en) * 2008-03-13 2018-05-15 Biotest Ag Agent for treating disease
EP2101173A1 (en) 2008-03-14 2009-09-16 Vivalis In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein
WO2010022341A1 (en) 2008-08-21 2010-02-25 The United State Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of enriching and using regulatory t cells
ES2335381B1 (es) 2008-09-24 2011-02-28 Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron Metodo in vitro y kit para el pronostico o prediccion de la respuestapor parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor tnfalfa.
CA2738598C (en) * 2008-09-29 2017-11-21 Biotest Ag Composition for treating disease

Also Published As

Publication number Publication date
CN102027017A (zh) 2011-04-20
MX2010010028A (es) 2011-08-17
WO2009121690A1 (en) 2009-10-08
US9334325B2 (en) 2016-05-10
RU2010141826A (ru) 2012-04-20
JP5597553B2 (ja) 2014-10-01
US20110059084A1 (en) 2011-03-10
EP2265643B1 (en) 2016-10-19
ZA201007215B (en) 2016-08-31
AU2009231325B2 (en) 2014-09-18
AU2009231325A1 (en) 2009-10-08
CA2718184A1 (en) 2009-10-08
RU2539110C2 (ru) 2015-01-10
BRPI0909048A2 (pt) 2015-11-24
EP2265643A1 (en) 2010-12-29
IL207891A0 (en) 2010-12-30
SG190598A1 (en) 2013-06-28
CR11724A (es) 2011-06-07
JP2011516416A (ja) 2011-05-26
KR20100135257A (ko) 2010-12-24

Similar Documents

Publication Publication Date Title
CO6311007A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+, efectiva a dosis bajas
CO6311006A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas
CO6311008A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
CU20070203A7 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
CL2011000774A1 (es) Formulacion farmaceutica que comprende el compuesto 4-[3-(4-ciclopropanocarbonil-piperazina-1-carbonil)-4-fluorobencil]-2h-ftalazin-1-ona en dispersion solida con un polimero de matriz; correspondiente a copovidona, util en el tratamiento del cancer.
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
BR112012023021A2 (pt) compostos de indazol e seus usos
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
NZ715686A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
MX358491B (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
BR112012016543A2 (pt) Tratamento com vb-201
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
CO6771406A2 (es) Una composición combinada
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
SE0950392L (sv) Sammansättning för behandling av hudåkommor
CR20110226A (es) Composición para tratar enfermedad
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
BR112013001462B8 (pt) Composições

Legal Events

Date Code Title Description
FC Application refused